Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

October 1, 2014

Primary Completion Date

December 1, 2019

Study Completion Date

December 1, 2020

Conditions
Stage III Esophageal Squamous Cell CarcinomaStage II Esophageal Squamous Cell Carcinoma
Interventions
DRUG

Megestrol(Yining)

Megestrol(Yining): 160mg/d, po,7 weeks in total, one week before chemoradiotherapy and one week after chemoradiotherapy.

RADIATION

radiotherapy

radiotherapy (radiation): 50Gy in total,2 Gy/d,5d/w.

OTHER

chemotherapy

capecitabine(Aibin):625mg/m2, bid d1-5; q1w, po,5 weeks in total or capecitabine(Aibin) plus Oxaliplatin(Aiheng):65mg/m2,d1,8, 22, 29,I.V. or cisplatin: 75mg/m2 d1,29 5-Fu:750mg/m2CIV24h d1-4,d29-32. The 3 regimens were Randomly distributed to patients.

Trial Locations (1)

471003

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang

All Listed Sponsors
lead

The First Affiliated Hospital of Henan University of Science and Technology

OTHER

NCT02644408 - Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy | Biotech Hunter | Biotech Hunter